[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636860":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":169,"collaborators":19,"id":171,"slug":172,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":19,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":19,"studyType":184,"phases":185,"briefSummary":187,"conditions":188,"keywords":19,"overallStatus":68,"whyStopped":19,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4256984","EXPERIMENTAL","LY4256984 administered intrathecally (IT)",[13],"Drug: LY4256984",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered IT",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Physicians interested in becoming principal investigators please contact","3176154559","clinical_inquiry_hub@lilly.com",[35,52,66,79,91,105,117,129,143,157],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"UZ Leuven","NOT_YET_RECRUITING","Leuven","3000","Belgium","BE",{"type":43,"coordinates":44},"Point",[45,46],4.70093,50.87959,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":19,"phoneExt":19,"email":19},"Philip Van Damme","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":37,"city":54,"state":19,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"University Hospital - London Health Sciences Centre","London","N6A 5A5","Canada","CA",{"type":43,"coordinates":59},[60,61],-81.23304,42.98339,{"lat":61,"lon":60},[64],{"name":65,"role":51,"phone":19,"phoneExt":19,"email":19},"Christen Shoesmith",{"facility":67,"status":68,"city":69,"state":19,"zip":70,"country":56,"countryCode":57,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"McGill University Health Centre","RECRUITING","Montreal","H4A 3J1",{"type":43,"coordinates":72},[73,74],-73.58781,45.50884,{"lat":74,"lon":73},[77],{"name":78,"role":51,"phone":19,"phoneExt":19,"email":19},"Angela Genge",{"facility":80,"status":37,"city":81,"state":19,"zip":82,"country":56,"countryCode":57,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Sunnybrook Research Institute","Toronto","M4N 3M5",{"type":43,"coordinates":84},[85,86],-79.39864,43.70643,{"lat":86,"lon":85},[89],{"name":90,"role":51,"phone":19,"phoneExt":19,"email":19},"Agessandro Abrahao",{"facility":92,"status":37,"city":93,"state":19,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Universitätsklinikum Schleswig-Holstein","Lübeck","23538","Germany","DE",{"type":43,"coordinates":98},[99,100],10.68729,53.86893,{"lat":100,"lon":99},[103],{"name":104,"role":51,"phone":19,"phoneExt":19,"email":19},"Julian Grosskreutz",{"facility":106,"status":37,"city":107,"state":19,"zip":108,"country":95,"countryCode":96,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Universitätsmedizin Rostock","Rostock","18147",{"type":43,"coordinates":110},[111,112],12.14049,54.0887,{"lat":112,"lon":111},[115],{"name":116,"role":51,"phone":19,"phoneExt":19,"email":19},"Andreas Hermann",{"facility":118,"status":37,"city":119,"state":19,"zip":120,"country":95,"countryCode":96,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Universitaetsklinikum Ulm","Ulm","89081",{"type":43,"coordinates":122},[123,124],9.99155,48.39841,{"lat":124,"lon":123},[127],{"name":128,"role":51,"phone":19,"phoneExt":19,"email":19},"Jochen Weishaupt",{"facility":130,"status":37,"city":131,"state":19,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Universitair Medisch Centrum Utrecht","Utrecht","3584 CX","Netherlands","NL",{"type":43,"coordinates":136},[137,138],5.12222,52.09083,{"lat":138,"lon":137},[141],{"name":142,"role":51,"phone":19,"phoneExt":19,"email":19},"Leonard H. Berg",{"facility":144,"status":37,"city":145,"state":19,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Hospital Universitari de Bellvitge","L'Hospitalet de Llobregat","08907","Spain","ES",{"type":43,"coordinates":150},[151,152],2.10028,41.35967,{"lat":152,"lon":151},[155],{"name":156,"role":51,"phone":19,"phoneExt":19,"email":19},"MONICA POVEDANO PANADES",{"facility":158,"status":37,"city":159,"state":19,"zip":160,"country":147,"countryCode":148,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":43,"coordinates":162},[163,164],-0.37966,39.47391,{"lat":164,"lon":163},[167],{"name":168,"role":51,"phone":19,"phoneExt":19,"email":19},"Juan Vazquez-Costa",{"type":170,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100636860","phase-1-a-substudy-of-ly4256984-in-participants-with-sporadic-amyotrophic-lateral-sclerosis-100636860",false,"NCT07571174","A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis","A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA","Participants must meet eligibility criteria in the \\[L0U-MC-OLMP\\] screening protocol before entry into the treatment study.\n\nInclusion Criteria:\n\n* Have completed the main treatment period\u002Fphase as well as any off-treatment period\u002Fphase of Study OWAA, the parent study for this ISA.\n\nExclusion Criteria:\n\n* The participant has conditions that preclude a lumbar puncture (LP), such as:\n\n  * A history of clinically significant back pain, back pathology, and\u002For back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP.\n  * Allergy to local anesthetics, such as lidocaine or its derivatives.\n  * A local infection at the intended site of the LP.\n  * Less than 100 giga per liter \\[(\\\u003C100 GI\u002FL) is equivalent to 100,000 per cubic millimeter (100,000\u002Fmm³)\\] platelets or clinically significant coagulation abnormality or significant active bleeding, or\n  * Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.","ALL","18 Years","80 Years",{"count":182,"type":183},32,"ESTIMATED","INTERVENTIONAL",[186],"PHASE1","The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.",[189],"Amyotrophic Lateral Sclerosis","2026-07-16",{"date":192,"type":193},"2026-07-17","ACTUAL",{"date":195,"type":193},"2026-05-14",{"date":197,"type":183},"2029-06",{"name":5,"class":6},10]